Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -24126.00x is 157% below its 3-year average of -9399.06x, near the low end of its 3-year range (-24126.00x–-775.33x).
As of the fiscal period ended Thursday, March 31, 2022. 49.85% below its 12-month average of -16099.80x.
Reported quarterly interest coverage; no daily interpolation. Q1 FY2022 (2022-03-31): -24126.00x.
INTEREST COVERAGE RATIO
-24126.00x
INTEREST COVERAGE RATIO AVG TTM
-16099.80x
INTEREST COVERAGE RATIO AVG 3Y
-9399.06x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-49.85%
CURRENT VS 3Y AVG
-156.69%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-4.99x
median of 387 covered companies
CURRENT VS SECTOR MEDIAN
-483386.97%
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$223.58M
Interest Coverage Ratio
-24126.00x
TTM Avg
-16099.80x
3Y Avg
-9399.06x
5Y Avg
N/A
Market Cap
$225.85M
Interest Coverage Ratio
-3.60x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$231.35M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$217.70M
Interest Coverage Ratio
N/A
TTM Avg
1274.61x
3Y Avg
1274.61x
5Y Avg
1274.61x
Market Cap
$230.02M
Interest Coverage Ratio
-8.56x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$232.73M
Interest Coverage Ratio
-133.11x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.50M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$213.22M
Interest Coverage Ratio
N/A
TTM Avg
39.15x
3Y Avg
39.15x
5Y Avg
39.15x
Market Cap
$212.35M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $223.58M | -24126.00x | -16099.80x | -9399.06x | N/A |
| Biodesix, Inc. (BDSX)vs › | $225.85M | -3.60x | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $231.35M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $217.70M | N/A | 1274.61x | 1274.61x | 1274.61x |
| MacroGenics, Inc. (MGNX)vs › | $230.02M | -8.56x | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $232.73M | -133.11x | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.50M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $213.22M | N/A | 39.15x | 39.15x | 39.15x |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.35M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.77M | 0.97x | 0.97x | 0.97x | 0.97x |
Interest Coverage
-24126.0x
Debt/Equity
0.06
Current Ratio
21.96
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2022-03-31 | -24126.00x |
| 2021-12-31 | -4866.00x |
| 2021-09-30 | -20197.00x |
| 2021-06-30 | -15541.00x |
| 2021-03-31 | -15769.00x |
| 2020-12-31 | -13291.00x |
| 2020-09-30 | -5974.00x |
| 2020-06-30 | -10914.00x |
| 2020-03-31 | -5252.00x |
| 2019-12-31 | -2728.00x |
| 2019-09-30 | -775.33x |
| 2019-06-30 | -1325.50x |
| 2019-03-31 | -1429.00x |
